Altered amyloid protein processing in platelets of patients with Alzheimer disease - PubMed (original) (raw)
Altered amyloid protein processing in platelets of patients with Alzheimer disease
R N Rosenberg et al. Arch Neurol. 1997 Feb.
Abstract
Background: beta-Amyloid peptide, the core component of neuritic plaques in brain areas in patients with Alzheimer disease (AD), is 1 cleavage product of the beta-amyloid precursor protein (APP) in neurons and platelets. Alternate cleavage products of intact 140- to 150-kd APPs in platelets include nonamyloidogenic 120- to 130-kd and 110-kd isoforms. The possible differential significance of these 2 isoforms, structurally similar to protease nexin II, is unknown.
Objective: To determine whether the ratio of the 120- to 130-kd APP isoform to the 110-kd APP isoform as processed in platelets correlates with the presence of AD and/or the apolipoprotein E4 (ApoE4) allele, which is a major risk factor for AD.
Setting: The Alzheimer Disease Center at The University of Texas Southwestern Medical Center at Dallas.
Methods: The APP isoforms were quantitated with the use of 2 different Western blot detection methods in platelets from 15 patients with AD and 19 control subjects in whom genotyping of apolipoprotein E was performed.
Results: The mean ratio of the 120- to 130-kd APP isoform to the 110-kd APP isoform in the patients with AD was significantly lower than that of the control subjects (5.98 vs 7.64; P = .03 [method 1] and 5.98 vs 7.92; P = .01 [method 2]) after adjusting for age and the increased incidence of ApoE4 in patients with AD. The lower APP ratios were also associated with increased age and with the presence of an ApoE4 allele.
Conclusions: The APP processing in platelets of patients with AD is different from that of control subjects. This difference, largely caused by factors other than the ApoE4 genotype, may reflect chronic platelet activation in patients with AD. The use of these data to estimate "AD risk," by using the APP isoform ratio, indicates an odds ratio of 1.75, suggesting possible utility as an adjunct in the diagnosis of AD. Moreover, these findings may relate to analogous alterations in APP processing that may occur in brain areas affected by AD.
Similar articles
- Differential level of platelet amyloid beta precursor protein isoforms: an early marker for Alzheimer disease.
Di Luca M, Pastorino L, Bianchetti A, Perez J, Vignolo LA, Lenzi GL, Trabucchi M, Cattabeni F, Padovani A. Di Luca M, et al. Arch Neurol. 1998 Sep;55(9):1195-200. doi: 10.1001/archneur.55.9.1195. Arch Neurol. 1998. PMID: 9740113 - The impact of risk factors of Alzheimer's disease in the Down syndrome.
Folin M, Baiguera S, Conconi MT, Pati T, Grandi C, Parnigotto PP, Nussdorfer GG. Folin M, et al. Int J Mol Med. 2003 Feb;11(2):267-70. Int J Mol Med. 2003. PMID: 12525890 - Amyloid precursor protein in platelets of patients with Alzheimer disease: effect of acetylcholinesterase inhibitor treatment.
Borroni B, Colciaghi F, Pastorino L, Pettenati C, Cottini E, Rozzini L, Monastero R, Lenzi GL, Cattabeni F, Di Luca M, Padovani A. Borroni B, et al. Arch Neurol. 2001 Mar;58(3):442-6. doi: 10.1001/archneur.58.3.442. Arch Neurol. 2001. PMID: 11255448 Clinical Trial. - Platelets as a peripheral district where to study pathogenetic mechanisms of alzheimer disease: the case of amyloid precursor protein.
Di Luca M, Colciaghi F, Pastorino L, Borroni B, Padovani A, Cattabeni F. Di Luca M, et al. Eur J Pharmacol. 2000 Sep 29;405(1-3):277-83. doi: 10.1016/s0014-2999(00)00559-8. Eur J Pharmacol. 2000. PMID: 11033334 Review. - Platelets provide human tissue to unravel pathogenic mechanisms of Alzheimer disease.
Cattabeni F, Colciaghi F, Di Luca M. Cattabeni F, et al. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Aug;28(5):763-70. doi: 10.1016/j.pnpbp.2004.05.022. Prog Neuropsychopharmacol Biol Psychiatry. 2004. PMID: 15363602 Review.
Cited by
- Biomarkers for Alzheimer disease in cerebrospinal fluid, urine, and blood.
Lönneborg A. Lönneborg A. Mol Diagn Ther. 2008;12(5):307-20. doi: 10.1007/BF03256296. Mol Diagn Ther. 2008. PMID: 18803429 Review. - Platelets and Alzheimer's disease: Potential of APP as a biomarker.
Evin G, Li QX. Evin G, et al. World J Psychiatry. 2012 Dec 22;2(6):102-13. doi: 10.5498/wjp.v2.i6.102. World J Psychiatry. 2012. PMID: 24175176 Free PMC article. Review. - Decoding the Role of Platelets and Related MicroRNAs in Aging and Neurodegenerative Disorders.
Espinosa-Parrilla Y, Gonzalez-Billault C, Fuentes E, Palomo I, Alarcón M. Espinosa-Parrilla Y, et al. Front Aging Neurosci. 2019 Jul 2;11:151. doi: 10.3389/fnagi.2019.00151. eCollection 2019. Front Aging Neurosci. 2019. PMID: 31312134 Free PMC article. Review. - Effects of ethanol on aggregation, serotonin release, and amyloid precursor protein processing in rat and human platelets.
Ehrlich D, Humpel C. Ehrlich D, et al. Platelets. 2014;25(1):16-22. doi: 10.3109/09537104.2013.764979. Epub 2013 Feb 12. Platelets. 2014. PMID: 23402285 Free PMC article. - Reduced platelet amyloid precursor protein ratio (APP ratio) predicts conversion from mild cognitive impairment to Alzheimer's disease.
Zainaghi IA, Talib LL, Diniz BS, Gattaz WF, Forlenza OV. Zainaghi IA, et al. J Neural Transm (Vienna). 2012 Jul;119(7):815-9. doi: 10.1007/s00702-012-0807-x. Epub 2012 May 10. J Neural Transm (Vienna). 2012. PMID: 22573143
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical